Skip to main content

Table 2 Number of patients with C-level disease activity at study entry in each BILAG body system

From: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

Body system Number of patients Contributing signs/symptoms* (number of patients)
I. General/Constitutional 11 Fatigue/malaise/lethargy (10)
   Anorexia/nausea/vomiting (1)
   Lymphadenopathy/splenomegaly (1)
   Pyrexia (documented) (1)
II. Mucocutaneous 1 Mild alopecia (1)
III. Neurological 10 Episodic migrainous headaches (8)
   Severe, unremitting headache (2)
IV Musculoskeletal 11 Arthralgia (10)
   Myalgia (9)
   Improving arthritis (1)
V. CV/Respiratory 2 Dyspnea (1)
   Pleuropericardial pain (1)
VI. Vasculitis 4 Raynaud's (3)
   Livido reticularis (1)
VII. Renal 4 Mild/stable proteinuria (4)
VIII. Hematology 11 Lymphocytopenia (< 1500 cells/μl) (10)
   Evidence of circulating anticoagulant (1)
   Decreased platelets (< 150,000/μl) (1)
  1. *Signs and symptoms that contributed to the C-level disease activity according to BILAG rules.